Obama was right for America.... Never stronger coalition, stock market highs, rebuilt banking, housing, Detroit strong, no inflation, saved the economy. NEWT,RYAB BOHNER all were dead wrong and would have destroyed America... Them and McCain would have had us in 5 wars this last 4 years. Talk how much wars cost and you can see Obama saved us hundreds of billions.
GETTING BIG GUNS- William M. Austin Appointed to Board of Directors
30 years experience- and a recognized leader who is currently President of Austin Lee Ventures, a Houston-based investment company.
Previously, he was Senior Vice President and Director of Exterran GP, LLC, and Senior Vice President and CFO of Valerus Compression Services, LP, both natural gas service companies. Prior to that, he was Senior Vice President and CFO of Key Energy Services, a leading oilfield services company. Earlier in his career Mr. Austin was a Managing Director of Bankers Trust Co., serving in the Leveraged Buyout group and as head of the Energy Group in Houston for 10 years.
Major interest in- " Appalachian Water Services, LLC (AWS), which owns and operates a wastewater treatment facility specifically designed to treat and recycle water resulting from the hydraulic fractu ring process in the Marcellus Shale area. 50-mile underground pipeline network in the Haynesville Shale area for the delivery of fresh water and removal of produced water, a fleet of approximately 1,100 trucks for delivery and collection, and approximately 5,700 storage tanks. The company also owns or leases 56 operating saltwater disposal wells in the Bakken, Marcellus/Utica, Haynesville, Eagle Ford, and Tuscaloosa Marine shale areas. The company and Halliburton work together in the Bakken Shale area to offer the H2O ForwardSM service to E&P companies. H2O Forward service allows customers to recycle waste streams of flowback and produced water for use in well completions, reducing the need for fresh water. The company provides logistics, transportation, storage, and overall fluid management services. As part of its environmental solution for solid waste, the company owns an oilfield solids disposal landfill in the Bakken Shale area. The landfill is located on a 60-acre site with permitted capacity of approximately 1.7 million cubic yards of airspace. NES owns several t
Its really not that hard to understand. Markets always over correct. Many of these oil plays have price to books of like 20% and way over sold
Sentiment: Strong Buy
The suit is based on WHAT? You must be clueless as ZMAPP is being tested and every thing Robert has said is coming true. The only suit that wins will be a counter. Both Roberts in the company Chairman and CEO are lawyers. Then there are the facts..... GO get #$%^&*() ed. Its a slam dunk for IBIO.
- Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer ______ The company's lead immunotherapy candidate, bavituximab is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. Bavituximab is our lead therapeutic PS-targeting antibody candidate, which has demonstrated broad therapeutic potential and represents a new approach to treating cancer. _______ BAVITUXIMAB - Phases 1 studies for Liver cancer, Breast cancer, rectal cancer, Melanoma cancer. ______ EBOLA antibodies- Peregrine's PS targeting antibodies have the potential to address a common immune evasion mechanism exploited by infectious pathogens. Exposed PS is a subject of increasing study by researchers worldwide as a result of its thoroughly documented . A phosphatidylserine-targeting antibody (PGN401, bavituximab) has previously been 21 shown to have broad-spectrum antiviral activity. Here, we demonstrate that PGN401 22 specifically binds to Ebola virus and recognizes infected cells. This study has shown that the PS-‐targeting antibody, PGN401, binds to EBOV-‐infected cells and to purified EBOV virions. Due to PGN401 having been used for several human clinical trials in cancer, from Phase I to III [13, 20, 21], its repurposing of use for filovirus therapy through 264 licensure or emergency use may present an attractive option. ______. Bavituximab (PGN401) is a monoclonal human -‐ chimeric antibody. _______ PGN401 has successfullycompleted several clinical trials, including Phase I in patients with advanced solid tumors and Phase II in patients with advanced breast cancer and non-‐small cell lung cancer (NSCLC) . It is now entering Phase III trials for NSCLC . Therefore, PGN401 is known to be safe in human studies and the pharmacokinetics of the antibody has been studied. The genus Ebolavirus includes five species (Bundibugyo ebolavirus, Reston ebolavirus, Sudan ebolavirus, Taï Forest ebolavirus and Zaire ebolavirus). Ebolavirus strain ebola (EBOV) is the only member of the Zaire 30 species of ebolavirus . The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Now in studies HEP C and HIV. ______________Targeted tumor Imaging. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc Cotara, our lead Tumor Necrosis Therapy (TNT) agent, and demonstrated promising results in a Phase II clinical trial in glioblastoma multiform (GBM) patients at first relapse. Patient treatment in this trial was completed and top-line data was presented in a poster session at the ASCO 2011 annual meeting. A novel approach to treating brain cancer, - statically Significant Tumor Growth Suppression With Single Agent Bavituximab Equivalent; Statistically Significant Increases in Ratios of Key Indicators of Immune Stimulation With Single Agent Bavituximab Equivalent- PS-targeting antibody and an anti-PD-1 antibody demonstrated statistically significant tumor growth inhibition in preclinical breast tumor models compared to anti-PD-1 alone," said Bruce Freimark, Ph.D., director, preclinical research, oncology at Peregrine Pharmaceuticals. "With these results we continue to see positive and consistent data of tumor growth suppression as well as decreases in important immune suppressive activities, making breast cancer a very promising indication for further clinical development." _____________ Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc which provides development and biomanufacturing services for both Peregrine and third-party customers. Avid which provides biomanufacturing services for its clients as well as products for our clinical trials. For oncology indications, our lead PS-targeting candidate bavituximab in combination with chemotherapy has demonstrated promising signs of anti-tumor activitiy and survival trends in patients with non-small cell lung cancer (NSCLC) and advanced breast cancer.
TRUMP is a Buffoon ............ He is Dicktator. He is worst then Biden when it comes to putting his foot in his mouth. HE is no politician. NOT that politicians are good but he is a complete DICKKT. COLORFUL , rich and on top of the business community yes, but a leader for the people HELLP NO! He would have us in a war faster then McCain. HIS arrogance would be enough in its self to isolate us from the world and set us back 20 years in world affairs. HAVE you not heard him say the world should respect and fear us that in its self would bring terrorist to our back door.
I am sure he is still looking in Hawaii and Africa... HE is about as clever as a mule is a horse race.
Most of the industry thinks they are full of short #$%$.....Blomberg think all the longs will sell as the shorts squeeze the price up... Its a fantasy by idiots who can be if it from their over played short position...
What could happen is war in the middle east and lines rigs and Isis blocking the straight. Short covering would send oilfutures through the roof.
Whats this fraud talk, Just because its a China stock? 80% of the stocks don't pay a dividend. This has been around for ever. no share holders have ever bought a China stock in total. Many have filled their portfolio with them. There are many great China stocks ... Many have made people rich. There is fraud over in China. Granted , but many good stocks also. With out proof you look like an idiot
Cant read a balance sheet or understand it has a 19 dollar book. No way is it going BK. The price to book for these stocks have never been better. The only times they got close in history they tacked on 200% gains the following couple years. Burn these idiot shorts here that don't understand oil. ITs time.
Storage is at 50%, 46% is normal. The idiots at Blomberg are short. ,we are supporting Iran fighters in Iraq. Isis gets the straights and Yemen and Syria is a powder keg. Oil could run very hard with news
Why do you think it is a scam if there is no ZMAP ? Some uniformed buyers only are here for the MAPP connection and other true longs know of the pipeline, plantibodies, proteins, antibodies, pipeline and true footprint on the industry. I have 20 pages of notes to inform you. What do you want to know about? The platform and partners? Pipeline? Partners? You must be really un educated if one small dis appointment makes it a scam..... Robert and what he said is not a scam.... His role in the industry is far from a scam. The other big pharma companies interest one day will not be a scam. The industry attention to quality,saving, time and lives are not a scam. Use of Plantibodies are not a scam. Having patents locked up in the USA are not a scam. Optimizing techniques are not a scam. PLEASE elaborate because you sir sound like the scam.
Bavituximab binds to phosphatidylserine which is exposed on the surface of certain atypical animal cells, including tumour cells and cells infected with any of six different families of virus. These viral families contain the viruses hepatitis C, influenza A and B, HIV 1 and 2, measles, respiratory syncytial virus, pichinde virus, which is a model for the Lassa virus, and Ebola virus Other cells are not affected since phosphatidylserine normally is only intracellular.
Bavituximab binds to various aminophospholipids and is dependent on interaction with plasma protein beta-2 glycoprotein I to mediate binding.
These target aminophospholipids, usually residing only on the inner leaflet of the plasma membrane of cells, become exposed in virally infected, damaged or malignant cells, and more generally in most cells undergoing the process of apoptosis.
The antibody's binding to phospholipids alerts the body’s immune system to attack the tumor endothelial cells, thrombosing the tumor's vascular network and/or attacking free floating virally infected and metastatic cells while potentially minimizing side effects in healthy tissues.
Data detailing the immune-stimulatory mechanism of action of PS-targeting antibodies, such as bavituximab, are the subject of a manuscript published in the October 2013 issue of the American Association for Cancer Research (AACR) journal, Cancer Immunology Research. Bavituximab is currently being evaluated in several solid tumor indications
Second-line non-squamous non-small cell lung cancer (NSCLC)
A phase III SUNRISE trial evaluating bavituximab plus docetaxel versus docetaxel plus placebo in approximately 600 patients at clinical sites worldwide, started in December 2013 and is expected to end in December 2016.
Final data from the 121-patient Phase II trial in 2nd line lung cancer showed increase of overall survival (OS) of 11.7 months in the 3 mg/kg bavituximab plus docetaxel arm compared to 7.3 months in the combined control arm, with a persistent separation in the Kaplan Meier survival curves (HR=0.662) Overall response rate (ORR) was 17.1% in the 3 mg/kg bavituximab plus docetaxel arm versus 11.3% in the combined control arm. Progression free survival was 4.2 months in the 3 mg/kg bavituximab plus docetaxel arm, versus 3.9 months in the combined control arm. Post study unblinding, vial coding discrepancies were discovered in the placebo and 1 mg/kg vials. As a result, data from these two arms were combined for data analysis.
First-line non-squamous non-small cell lung cancer (NSCLC)
Interim data from the Phase Ib investigator-sponsored trial (IST) of immunotherapy bavituximab in combination with the chemotherapies pemetrexed and carboplatin in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). Data from this single-arm, open-label, multi-center trial show an overall tumor response (ORR) of 35%, a median progression-free-survival (PFS) of 4.8 months, and a median overall survival (OS) of 12.2 months.
Phase I open label, two-arm, randomized, single-center Phase Ib trial of bavituximab plus ipilimumab (an anti-CTLA-4 antibody), in 24 patients with advanced melanoma. The study started in April 2014 and is expected to end in March 2016. Previously, preclinical studies showed that PS targeting antibodies (such as bavituximab) enhance the anti-tumor activity of anti-CTLA-4 and anti-PD-1 antibodies. Tumor growth inhibition correlates with infiltration of immune cells in tumors and induction of adaptive immunity. The combination of these mechanisms promotes strong, localized, anti-tumor responses without the side-effects of systemic immune activation.
Interim data from a Phase I trial evaluating bavituximab plus paclitaxel therapy in patients with HER2-negative metastatic breast cancer (MBC) showed that 85% of patients achieved an objective tumor response, including 15% of patients achieving a complete response (CR) measured in accordance with RECIST criteria.
A phase II trial of bavituximab used with docetaxel against advanced breast cancer has yielded median progression-free survival (PFS) data of 7.4 months, a best overall response rate of 61% (28 of 46 patients) with 11% (5 of 46) of the patients achieving a clinical complete response. (This compares favorably to a separately published study of a similar patient population receiving docetaxel alone, which showed an objective response rate of only 41% with no complete responses.) 
A phase II trial of bavituximab used with paclitaxel and carboplatin chemotherapy against locally advanced or metastatic breast cancer has yielded 23.2 month median overall survival (OS) in patients with locally advanced or metastatic breast cancer. In a separate published study using a similar chemotherapy regimen of carboplatin and paclitaxel(1), median OS was 16.0 months in a similar patient population.
Advanced liver cancer
Data from the Phase I portion of the Phase I/II trial evaluating bavituximab plus sorafenib in patients with advanced hepatocellular carcinoma (HCC) in 56 patients showed no dose limiting toxicity (DLT), no grade 3 or 4 adverse events, and common toxicities limited to sorafenib. Currently, this study is in Phase II, and is expected to end in December 2014.
Advanced pancreatic cancer
Results from a randomized Phase II trial of bavituximab plus gemcitabine in patients with non-resectable Stage IV pancreatic cancer demonstrated 28% overall response rate (ORR) versus 13% in the control arm, and 5.6 months overall survival (OS) versus 5.2 months in the control arm (HR=0.75), including a delayed separation in the Kaplan-Meier survival curve that is commonly seen in clinical studies of promising cancer immunotherapies
They are delusional if they think they can drive it down much further. EVEN id oil goes a little lower the assets and value will hold this up now. YESSS they made good money and only the stupid one will remain here and not cover. ITS not the never ending short. All good thinks come to an end and say goodbye shorts.